Market Incident
Public · Developing
AI compiled from Infoway · 4 analyzed stories
Rayonier Advanced Materials (RYAM) Reports $229M Q3 Loss, Including $221M Impairments
Rayonier Advanced Materials reported a preliminary third-quarter loss of $229 million, including $221 million in non-cash impairments, compared with a $4 million loss a year earlier. The company said its strategic review is targeted to conclude in Q1 2027.
Published:
Updated:
What happened
Rayonier Advanced Materials reported a preliminary third-quarter loss of $229 million, including $221 million in non-cash asset write-downs. Other supplied headlines give the loss as $230 million and $3.40 per share, and report sales of $383 million. The company aims to finish its strategic review in Q1 2027.
Global impact / market context
The large reported loss may concern investors, but most of it came from non-cash write-downs, which are not cash paid out in the quarter. The supplied information does not explain the loss or show how the business is performing beyond the sales figure.
What to watch
- Check the company’s final third-quarter results to confirm the preliminary loss and write-down figures.
- Check any explanation of the $221 million write-downs to understand what assets were marked down and why.
- Check for updates to the strategic review and whether the company still expects it to conclude in Q1 2027.
Affected assets
- Rayonier Advanced Materials Inc.
Evidence
- Infoway News — Rayonier Advd Materials 3Q Sales $383M >RYAM
- Infoway News — Rayonier Advd Materials 3Q Loss $230M >RYAM
- Infoway News — Rayonier Advd Materials 3Q Loss/Shr $3.40 >RYAM
- Infoway News — Rayonier Advanced Materials (RYAM) Reports $229M Q3 Loss, Including $221M Impairments
- Incident timeline — Rayonier Advd Materials 3Q Sales $383M >RYAM
- Incident timeline — Rayonier Advd Materials 3Q Loss $230M >RYAM
- Incident timeline — Rayonier Advd Materials 3Q Loss/Shr $3.40 >RYAM
- Incident timeline — Rayonier Advanced Materials (RYAM) Reports $229M Q3 Loss, Including $221M Impairments